The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT-EHA CAR-T 2019 | CAR T-cell therapy economics in the real world
Duane Schulthess, BA, from Vital Transformation, Flanders, Belgium, discusses the necessity of real-world data for demonstrating the value of CAR T-cell therapy to health technology assessors. Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, Mr Schulthess reports that to overcome the barriers across both the approval process and reimbursement, it is crucial to prove the real-world safety, efficacy and cost-effectiveness of CAR T-cell therapy. This meeting was co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
